Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03742193
Other study ID # 2018LLS-NO.84-3
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date August 11, 2019
Est. completion date December 30, 2023

Study information

Verified date October 2023
Source Ruijin Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to evaluate the efficacy and safety of Second-line chemotherapy combined with Apatinib for the patients with resectable pulmonary metastasis of osteosarcoma.


Description:

After standard chemotherapy and surgery for the localized disease, pulmonary metastases of osteosarcoma occurs in up to 40% of cases and still remain challenging without satisfactory regimen. Apatinib is a oral kinase inhibitor of receptor tyrosine targeting VEGFR2. A pilot study indicated that Apatinib improved the PFS after multi-line chemotherapy failure, and might partly reversed chemo-refractory status for advanced osteosarcoma. Thus, the investigators explored the efficacy of combining Apatinib with current available second-line chemotherapy compared to chemotherapy alone for treating first resectable pulmonary metastases of osteosarcoma following the failure of first-line chemotherapy and wide/radical-margin surgery. Participants will receive 250 mg of apatinib twice daily combined with gemcitabine-docetaxel (GD) regimen before and after the surgical resection of the pulmonary metastases. Osteosarcoma patients with pulmonary recurrence only at baseline will be recruited in the study. The primary end point is progression-free survival rate (PFR) compared with historical control. A12 month PFR of 30% or less is considered inactive, while a 12 month PFR of 50% or greater is regarded as of interest for additional development. With a type I error rate of 5% and a power of 83%, the number of patients needed for this design is 43.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 43
Est. completion date December 30, 2023
Est. primary completion date November 15, 2023
Accepts healthy volunteers No
Gender All
Age group 10 Years to 50 Years
Eligibility Inclusion Criteria: - age between 10 and 50 years; - diagnosis of histologically confirmed high grade osteosarcoma; - identification of pulmonary metastases without the existence of local recurrence(previous re-resection of local recurrence with wide margin is allowed). - resectable pulmonary nodule(s), defined as nodule(s) that are removable by wedge resection/ segmentectomy/lobectomy without necessitating a pneumonectomy (e.g., nodules immediately adjacent to the main stem bronchus or main pulmonary vessels) - prior treatment consisted of standard National Comprehensive Cancer Network (NCCN) guideline recommended first-line chemotherapy - wide/radical-margin surgical resection of the primary tumor completed at least 4 weeks before enrollment. - Eastern Cooperative Oncology Group(ECOG) performance status 0-2 with a life expectancy >3 months; - adequate renal, hepatic, and hemopoietic function; - normal or controlled blood pressure; - no thoracic comorbidities with adequate pulmonary function eligible for thoracic surgery Exclusion Criteria: - previously exposed to GD chemotherapy or VEGFR2 Tyrosine-kinase inhibitors (TKIs); - existence of local recurrence; - have had other kinds of malignant tumors at the same time; - cardiac insufficiency or arrhythmia; - uncontrolled complications, such as diabetes mellitus and so on; - coagulation disorders or Hemorrhagic diseases ; - metastases considered unresectable or borderline resectable at baseline - intolerable of thoracis surgery - pleural or peritoneal effusion that needs to be handled by surgical treatment; - combined with other infections or wounds - wound dystrophy, poor soft-tissue around implantation or other wound complications risky of non-healing given angiogenesis inhibitor assessed by the investigators

Study Design


Intervention

Drug:
Apatinib
Apatinib 250mg tablet by mouth, bid. 48 hrs break before and 96 hrs after the surgical resection of the pulmonary metastases.
GD regimen
One cycle: gemcitabine 900 mg/m^2 over 90 min on Day 1, and gemcitabine 900 mg/m^2 and docetaxel 75 mg/m^2 on Day 8. Every 21 days were eligible. 1~2 -week break before and 2-week break after the surgical resection of the pulmonary metastases is taken.

Locations

Country Name City State
China Ruijin Hospital Shanghai Jiao Tong University School of Medicine Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Ruijin Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Exploratory outcome: Subgroup analysis of progression-free survival(PFS) The PFS for each subgroups in terms of clinicopathological characteristics (age, gender, histological type, solitary or multiple metastases, unilateral or bilateral metastases, early or late metastases, calcifying or non-calcifying lesions, with or without lesion cavitation, with or without AEs [especially pneumothorax, hand-foot skin reactions, hair depigmentation], etc) Baseline until disease progression or death, whichever occurs first (followed through study completion, an average of 1.5 years)
Other Exploratory outcome: The correlation of potential pathological biomarker with PFS The correlation between the expression of VEGFR2, CD34, Ki-67 and immune cell infiltration by immunohistochemistry and PFS Baseline until disease progression or death, whichever occurs first (followed through study completion, an average of 1.5 years)
Other Exploratory outcome: Tumor response pre-metastasectomy as a predictor of PFS to compare the PFS of the three group according to tumor response pre-metastasectomy (group1: CR/PR, group2: SD, group3 PD) Baseline until disease progression or death, whichever occurs first (followed through study completion, an average of 1.5 years)
Other Exploratory outcome: Tumor cavitation as a prognostic factor for oncological outcome to compare the predictive value of the Crabb's modified RECIST criteria with the original RECIST 1.1 criteria in terms of PFS and OS Baseline until disease progression or death, whichever occurs first (followed through study completion, an average of 1.5 years)
Other Exploratory outcome: AEs of the targeted therapy as prognostic factors for oncological outcome, especially pulmonary lesion cavitation/pneumothorax and hair depigmentation to correlate the incidence of targeted therapy related AEs (especially pneumothorax, hand foot skin reactions, skin and hair depigmentation and fatigue)with the PFS/OS for the treatment arm. Baseline until disease progression or death, whichever occurs first (followed through study completion, an average of 1.5 years)
Other Correlation of KDR 604 polymorphism with pulmonary lesion cavitation/pneumothorax and with PFS According to our previous retrospective analysis, we aim the validate the correlation of KDR 604 AA,AG,GG genotype with the incidence of pulmonary lesion cavitation/pneumothorax and PFS among all patients. Baseline until disease progression or death, whichever occurs first (followed through study completion, an average of 1.5 years)
Other Exploratory outcome: 1.0-mm CT scan for the early identification small lung nodule as pulmonary recurrence to compare the diagnostic value of the 1.0 mm versus 5.0 mm CT scan for the radiological evaluation of small lung nodule as tumor recurrence Baseline until disease progression or death, whichever occurs first (followed through study completion, an average of 1.5 years)
Primary 12 months Progression-free survival rate(12mPFR) The proportion of patients with progression-free survival at 12 months according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1). A 12mPFR of 30% or less is considered inactive, while a 12mPFR of 50% or greater is regarded as of interest for additional development 12 months from the recruitment of the study
Secondary Overall survival (OS) calculated from the date of treatment start until last follow-up or death, whichever comes first. Baseline until death, followed through study completion, an average of 2 years
Secondary Total resectability The number of patients undergoing pre-planned metastasectomy divided by the number of patients considered resectable at baseline after neoadjuvant systemic therapy, an average of 8~9 weeks
Secondary Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] The occurrence of each adverse events(AEs), severe AEs(SAEs) and death according the CTCAE_5.0 through study completion, an average of 1 years
Secondary Objective response rate (ORR) Complete Response(CR)+Partial Response(PR) after neoadjuvant systemic therapy after neoadjuvant systemic therapy, an average of 8~9 weeks
Secondary Clinical benefit rate (CBR) CR+PR+stable disease (SD) after neoadjuvant systemic therapy after neoadjuvant systemic therapy, an average of 8~9 weeks
Secondary Progression free survival (PFS) Progression free survival according to RECIST 1.1 Baseline until disease progression or death, whichever occurs first (followed through study completion, an average of 1.5 years)
Secondary OS rate the proportion of OS at 12, 24 months 12 and 24 months from baseline
See also
  Status Clinical Trial Phase
Completed NCT00026780 - Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
Not yet recruiting NCT05515068 - Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas
Completed NCT02383901 - A Retrospective Non-intervention Study to Characterize FOlate Rescue Treatment in Osteosarcoma Patients Treated With HDMTX N/A
Active, not recruiting NCT01758666 - A Clinical Research on the Relation of Blood Drug Concentration and Calcium Folinate Rescued in High-dose MTX Therapy N/A
Completed NCT01674101 - Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy N/A
Completed NCT01615640 - Diffusion Study on Patients With Osteosarcoma
Completed NCT00523419 - Chemotherapy for Patients With Osteosarcoma Phase 2
Completed NCT00520936 - A Study of Pemetrexed in Children With Recurrent Cancer Phase 2
Completed NCT00132158 - ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors Phase 1
Not yet recruiting NCT04319874 - Phase II Clinical Trial Scheme of Ganoderma Lucidum Spore Powder for Postoperative Chemotherapy of Osteosarcoma Phase 2
Recruiting NCT06029218 - Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy N/A
Recruiting NCT05642455 - SPEARHEAD-3 Pediatric Study Phase 1/Phase 2
Recruiting NCT06117878 - Safety and Efficacy of NK510 to Treat Osteosarcoma and Soft Tissue Sarcoma Early Phase 1
Not yet recruiting NCT04316091 - A Phase I Clinical Trial of Neoadjuvant Chemotherapy With/Without SPIONs/SMF for Patients With Osteosarcoma Phase 1
Recruiting NCT03932058 - Proteomics Research of Osteosarcoma
Withdrawn NCT01236586 - RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia Phase 1
Completed NCT00743496 - A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma Phase 1
Recruiting NCT04040205 - Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration Phase 2
Recruiting NCT05970497 - A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors Phase 1
Active, not recruiting NCT03628209 - Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma Phase 1/Phase 2